Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset

Documenti analoghi

• Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM ‐ POWR Study
  di: Mark T. Reding, et al.
  Pubblicazione: (2025)
• Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
  di: Margareth C. Ozelo, et al.
  Pubblicazione: (2026)
• ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B
  di: Fabienne Volot, et al.
  Pubblicazione: (2024)
• Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half‐Life FVIII in Hemophilia A: A‐SURE Study
  di: Johannes Oldenburg, et al.
  Pubblicazione: (2024)
• Predictive and Prognostic Significance of Patient‐Reported Outcomes for Survival and Adverse Events in Daratumumab‐Treated Multiple Myeloma
  di: Ahmad Y. Abuhelwa, et al.
  Pubblicazione: (2025)